

UCSF

UC San Francisco Previously Published Works

Title

Viral and host mediators of non-suppressible HIV-1 viremia

Permalink

<https://escholarship.org/uc/item/4v72b73j>

Journal

Nature Medicine, 29(12)

ISSN

1078-8956

Authors

Mohammadi, Abbas

Etemad, Behzad

Zhang, Xin

et al.

Publication Date

2023-12-01

DOI

10.1038/s41591-023-02611-1

Peer reviewed

Viral and host mediators of non-suppressible HIV-1 viremia

Received: 7 March 2023

Accepted: 25 September 2023

Published online: 13 November 2023

 Check for updates

Abbas Mohammadi^{1,2}, Behzad Etemad¹, Xin Zhang^{1,3}, Yijia Li^{1,4,5}, Gregory J. Bedwell⁶, Radwa Sharaf¹, Autumn Kittilson¹, Meghan Melberg¹, Charles R. Crain⁷, Anna K. Traunbauer^{7,8}, Colline Wong¹, Jesse Fajnzylber¹, Daniel P. Worrall⁷, Alex Rosenthal¹, Hannah Jordan¹, Nikolaus Jilg^{1,4}, Clarety Kaseke⁷, Francoise Giguel¹, Xiaodong Lian⁷, Rinki Deo¹, Elisabeth Gillespie¹, Rida Chishti¹, Sara Abrha¹, Taylor Adams¹, Abigail Siagian¹, Dominic Dorazio⁹, Peter L. Anderson¹⁰, Steven G. Deeks¹¹, Michael M. Lederman⁹, Sigal Yawetz¹, Daniel R. Kuritzkes¹, Mathias D. Lichterfeld^{1,4,7}, Scott Sieg⁹, Athe Tsibris¹, Mary Carrington^{7,12,13}, Zabrina L. Brumme^{14,15}, Jose R. Castillo-Mancilla^{10,16}, Alan N. Engelman⁶, Gaurav D. Gaiha^{4,7} & Jonathan Z. Li¹✉

Non-suppressible HIV-1 viremia (NSV) is defined as persistent low-level viremia on antiretroviral therapy (ART) without evidence of ART non-adherence or significant drug resistance. Unraveling the mechanisms behind NSV would broaden our understanding of HIV-1 persistence. Here we analyzed plasma virus sequences in eight ART-treated individuals with NSV (88% male) and show that they are composed of large clones without evidence of viral evolution over time in those with longitudinal samples. We defined proviruses that match plasma HIV-1 RNA sequences as ‘producer proviruses’, and those that did not as ‘non-producer proviruses’. Non-suppressible viremia arose from expanded clones of producer proviruses that were significantly larger than the genome-intact proviral reservoir of ART-suppressed individuals. Integration sites of producer proviruses were enriched in proximity to the activating H3K36me3 epigenetic mark. CD4⁺ T cells from participants with NSV demonstrated upregulation of anti-apoptotic genes and downregulation of pro-apoptotic and type I/II interferon-related pathways. Furthermore, participants with NSV showed significantly lower HIV-specific CD8⁺ T cell responses compared with untreated viremic controllers with similar viral loads. We identified potential critical host and viral mediators of NSV that may represent targets to disrupt HIV-1 persistence.

For the majority of persons with human immunodeficiency virus (PWH), antiretroviral therapy (ART) suppresses HIV-1 RNA to below the level of commercial assay detection^{1–3}. However, a subset of PWH demonstrate persistent low-level viremia while on ART^{6,7}, a condition that not

only represents a clinical conundrum for the clinician but can lead to substantial stigma and distress for the patient. Persistent low-level viremia has historically been attributed to suboptimal ART adherence and/or accumulating human immunodeficiency virus-1 (HIV-1) drug

A full list of affiliations appears at the end of the paper. ✉ e-mail: jli@bwh.harvard.edu

resistance^{8,9}. Previous studies supporting the presence of active viral replication have reported that ART resistance mutations can accumulate when viremia persists in the low but detectable range^{10,11} and that low-level viremia can increase the risk of virologic failure¹². However, there has been intriguing evidence that persistent low-level viremia can be maintained for long periods without leading to high-level virologic failure or the development of new resistance mutations^{13–18}. This subset of individuals with persistent low-level viremia without evidence of ART non-adherence or meaningful drug resistance are defined as having non-suppressible HIV-1 viremia (NSV).

Clonal expansion of HIV-infected cells represents a key contributing factor for HIV-1 persistence, and recent studies have suggested that this plays an important role in NSV as well. Halvas et al. also studied a cohort of participants with NSV, reporting that the majority of plasma variants were composed of clusters of identical sequences without signs of viral evolution, which is consistent with the plasma viruses originating from a transcriptionally active viral reservoir rather than new rounds of infection¹. While NSV was fueled by large populations of clonally expanded HIV-infected cells, the mechanisms that lead to the establishment and maintenance of NSV, and the NSV-generating proviral reservoirs, remain understudied. In this Article, we characterized a cohort of eight participants with NSV, and performed in-depth ART drug concentration testing, alongside viral and host cell genetics/genomics and immune profiling. We identified features of host integration sites that differentiated proviruses fueling NSV from those that were not contributory. Transcriptomic and immunologic phenotyping studies further highlight potentially permissive host cell and cellular immune environments in patients with NSV. These results provide the most comprehensive evaluation so far of the viral, cellular and immune mediators of NSV.

Participant characteristics and assessment of ARV levels

We enrolled eight participants with ongoing NSV, 88% men, with a median age of 60 years and median ART duration of 10 years. The median duration of virologic suppression before the NSV and duration of NSV for all participants were 4 and 2 years, respectively. During the NSV episodes, the median viral load was 143 copies ml⁻¹ and the median CD4 count was 798 cells μl⁻¹ (Table 1 and Supplementary Table 1). Individual participant characteristics, ART regimens and genotypic susceptibility scores (GSS)¹⁹ of plasma viruses sequenced during NSV are presented in Supplementary Table 1. All participants were receiving at least two active antiretroviral drugs during the NSV episodes. Characteristics of the ART-suppressed and viremic controllers (VCs) historical comparator participants are presented in Supplementary Tables 2–4.

We assessed ART adherence by quantifying antiretroviral (and their anabolites) drug concentrations in plasma or through dried blood spot (DBS) testing. LV1 and LV2 had plasma dolutegravir and darunavir concentrations consistent with ongoing ART use (Supplementary Table 5). LV3 and LV5–9 had DBS tests for tenofovir (TFV-DP, a measure of cumulative tenofovir/tenofovir alafenamide adherence)^{20,21} and emtricitabine (FTC-TP, a measure of recent emtricitabine dosing within the preceding 7 days)^{22,23}. The median (range) FTC-TP level was 5 (4.4–6.7) pmol per punch and TFV-DP level was 3,702 (2,771–6,684) fmol per punch²⁴. These concentrations are consistent with expected levels in ART-suppressed individuals, including the highest odds of suppression and lowest odds of future viremia^{20,23,25,26}, suggesting that our participants with NSV had both high levels of short-term and cumulative ART adherence (Supplementary Fig. 1 and Supplementary Table 5).

Plasma NSV were composed of large clones without evolution

HIV-1 integration targeting preferences are demarcated by various features of active chromatin, including transcription²⁷, histone

Table 1 | Characteristics of NSV and ART-suppressed control participant cohorts

Characteristic	NSV (n=8)	Control for HIV-1-specific CD8 ⁺ T cell (n=7)	Control from ACTG (n=11)	
Sex, number (%)	Male	7 (88)	5 (71)	6 (42)
Age (years) (median [IQR ^a])		60 [55, 61]	62 [52, 68]	45 [40, 50]
Race/ethnicity (%)	African American	2 (25)	2 (29)	3 (27)
	Native American	1 (12)	0	0
	Caucasian	4 (50)	5 (71)	7 (63)
	Hispanic	1 (12)	0	1 (10)
Years on ART (median [IQR])		10 [7, 14]	12 [10, 13]	6 [5, 7]
Years with NSV ^b (median [IQR])		4 [3, 9]	NA ^d	NA ^d
Years with suppression (median [IQR])		2 [1, 7]	12 [10, 13]	6 [5, 7]
Viral load copies ml ⁻¹ (median [IQR])		143 [87, 536]	BLD ^e	BLD ^e
CD4 count cells μl ⁻¹ (median [IQR])		798 [581, 1,008]	793 [617, 949]	806 [713, 1,208]

^aIQR, interquartile range. ^bNSV, non-suppressible HIV-1 residual viremia. ^cVirologic suppression before the NSV. ^dNA, not applicable. ^eBLD, below level of detection (HIV-1 plasma viral below limit of detection).

epigenetic marks²⁸ and nuclear speckle proximity²⁹. The reservoir landscape changes over time in response to ART and the host immune response to a quasi-homeostatic state marked by cell loss and clonal expansion^{30–36}. A key goal of this study was to assess aspects of host proviruses that contributed to NSV. Longitudinal single-genome sequencing of near-full-length proviruses and plasma HIV-1 *pol-env* RNA was performed.

A total of 1,987 single-genome proviral sequences and 222 single-genome plasma sequences were generated for the eight participants with NSV. Longitudinal plasma HIV-1 sequences were obtained for four participants with available sampling (LV1, LV7, LV8 and LV9), at a median 4.5 time points, an average of 9.7 months apart (Fig. 1a and Extended Data Fig. 1). While the ART regimen was adjusted during the NSV for some participants, virologic suppression was not achieved (Extended Data Fig. 1).

Phylogenetic analysis confirmed that sequences from each participant partitioned into separate clusters (Supplementary Fig. 2). We next looked for evidence of longitudinal HIV-1 sequence changes consistent with the active infection of new cells. Neighbor joining trees of proviral and plasma sequences for these eight participants instead showed that the plasma sequences were dominated by one or two clones, with no evidence of viral evolution, consistent with plasma virus originating from a transcriptionally active population of HIV-1-infected cells (Figs. 1b and 2a). For the initial analysis, proviral sequences were considered intact if they either did not harbor obvious defects or were linked to plasma sequences. At the time of study entry, the two largest plasma HIV-1 clones accounted for a median 71% (Q1–Q3: 27–83%) of all plasma sequences and were linked to a median 26% (Q1–Q3: 14–61%) of all intact proviral sequences (Extended Data Fig. 2a). Overall, intact proviruses accounted for a median 4.5% (Q1–Q3: 3.8–15%) of the proviral reservoir, with a high degree of variation evident from two participants (LV2 and LV9). LV2 and LV9 proviruses were dominated by several large clones of intact sequences that represented 76% and 34% of their total peripheral




Fig. 1 | Example participant with non-suppressible viremia (LV1). **a**, Viral loads and CD4⁺ T cell count from the time of virologic suppression. Downward blue and orange arrows indicate timing of drug resistance and plasma drug level testing, respectively. Sampling times for viral genetic analyses are in black arrows. Antiretroviral resistance mutations from both clinical testing and the largest plasma clone from single-genome sequencing are shown in the table insert. The “(C)” denotes a clinical resistance testing result. **b**, Neighbor joining trees of proviral and plasma *pol-env* sequences in blue and red, respectively. Producers

defined as proviruses with exact matches to plasma HIV-1 RNA sequences. Non-producers are proviruses that do not match any plasma HIV-1 RNA sequences. Shape indicates sampling time point, corresponding to black arrows in **a**. RPV, rilpivirine; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine; ATV/r, atazanavir/ritonavir; TAF, tenofovir alafenamide; DTG, dolutegravir; DRV/r, darunavir/ritonavir; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; IN, integrase; PI, protease inhibitor.

blood mononuclear cell (PBMC) proviral reservoirs, respectively (Extended Data Figs. 2b,c).

We categorized proviruses as producers if they matched a plasma sequence and as non-producers if they did not. There was a wide range of producer proviruses within the reservoir. For LV2, the PBMC proviral reservoir was largely composed of one large producer clone representing 98% of intact proviruses, which matched the large plasma NSV clone (Fig. 2a). In contrast, LV3 had the smallest producer reservoir size, representing 3.5% of total intact sequences. These results demonstrate that, while these individuals share a common

NSV phenotype, their proviral landscape can be highly heterogeneous (Extended Data Fig. 2b,c).

We next compared the size of the intact and defective reservoir sizes between the participants with NSV and a control group of ten ART-suppressed participants (Supplementary Table 2). Participants with NSV had a numerically larger total and significantly larger intact PBMC proviral reservoir (NSV versus ART-suppressed: median total proviral genomes 34 versus 18 proviruses per million cells, $P = 0.08$; and median intact proviral genomes 4.3 versus 0.1 proviruses per million cells, $P = 0.001$). Specifically, the size of the producer proviral reservoir




Fig. 2 | Sequencing overview of the non-suppressible viremia cohort.
a, Neighbor joining trees show intact proviral and plasma sequences from different time points. The host integration sites of the producer proviruses are labeled. **b**, Comparison of reservoir size (number of proviral sequences per million cells) for producer proviruses versus non-producer proviruses in

participants with NSV versus intact proviral reservoir size of ART-suppressed individuals. Median and interquartile ranges are labeled in the violin plot. Two-sided Wilcoxon matched-pairs signed-rank test and Mann-Whitney *U* tests were used for comparisons.

was significantly larger in the participants with NSV than either the non-producer intact proviral reservoir in these participants or the intact proviral reservoir in the ART-suppressed participants (Fig. 2b). In addition, the participants with NSV had a smaller number of proviruses with large deletions (median 2.6 versus 10.7 proviruses per million cells, $P = 0.006$). These results suggest that an enlarged producer reservoir size could be a contributing factor to NSV.

Integration site and epigenetic signatures of producers

The location and chromatin landscape of HIV-1 proviral integration sites can modulate the extent of proviral transcriptional activity^{37,38}. We accordingly evaluated whether certain integration site features differentiated the producer, non-producer and defective proviruses. Using the Matched Integration Site and Proviral Sequencing (MIP-seq) protocol³⁹, we identified host chromosomal integration sites for 11 producer, 21 intact non-producer and 44 defective proviruses across all participants with NSV (we were unable to identify an integration site for the LV3 producer clone). Integration sites were identified across all autosomal and sex chromosomes with the exception of chromosome

21 (Fig. 3a). Compared with non-producer and defective proviruses, producer proviral integration sites were enriched in chromosome 19. Twenty-seven percent (3/11) of producer proviruses were located in chromosome 19 compared with none of the 21 non-producer and 44 defective proviruses (producer versus non-producer $P = 0.03$ and producer versus defective $P = 0.006$, Fig. 3b).

We also observed significant enrichment of producer proviruses in proximity to two epigenetic markers. Using chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from primary CD4⁺ T cells published on the ROADMAP database⁴⁰, we detected significantly higher ChIP-seq peak numbers for the H3K36me3 and H3K9me3 histone marks in proximity to producer integration sites compared with either non-producer or defective integration sites (Fig. 3c). We calculated the level of plasma viral load contributed by the producer provirus, which we designate as the plasma clone viral load. We observed a significant positive correlation between the number of H3K36me3 ChIP-seq reads in proximity to the producer proviruses integration sites and the plasma clone viral load (Spearman $r = 0.83$, $P = 0.001$, Fig. 3d). Proximity to H3K36me3 has been linked to proviral gene expression^{38,41}, suggesting that producer proviruses are enriched




Fig. 3 | Integration sites and chromatin features of HIV-1 proviruses. **a**, Circos plot showing the location of each integration site across human chromosomes. **b**, Karyotyping heatmap showing the percentage of integration sites in each human chromosome for different classes of proviruses. Fisher's exact test was used. **c**, Number of peaks for key histone marks in 10-kb regions flanking the proviral integration sites. Center lines represent medians. We used Tukey boxplots, in which boxes represent median values and first–third quartiles. Two-sided

Kruskal–Wallis test was used to evaluate if there was significant differences among three groups and if so, two-sided Mann–Whitney *U* test was used to compare between-group differences. **d**, Correlation between enrichment of H3K36me3 histone marks near producer proviral integration sites and plasma clone viral loads (viral load multiplied by fraction of plasma sequences matching the producer provirus). Host gene integration sites are labeled. Two-sided Spearman correlation test was used. VL, viral load.

near transcriptionally active regions of the chromosome and that producer proviruses could potentially leverage cellular transcriptional machinery for proviral expression and virion production³⁷. In addition, a higher number of proximal ChIP–seq peak numbers for two other activating histone marks (H3K27ac and H3K4me1) were linked to greater expression of host genes containing integrated proviruses (Extended Data Fig. 3a), although these histone marks were not enriched near producer proviruses.

There were a number of chromosomal features that were not associated with the producer cell proviral phenotype. Distance to transcriptional start sites (TSSs) was statistically indistinguishable between producer, non-producer and defective proviruses, regardless of the orientation of the host gene and provirus (Extended Data Fig. 3b–d). We also did not detect any significant differences between producer, non-producer and defective proviral classes and their

distance to heterochromatic centromeres or the fraction of integration into transcriptionally active speckle-associated domains (Extended Data Fig. 3e,f). Finally, using RNA-seq analysis from CD4⁺ T cells of participants with NSV, we detected no significant differences in host gene transcript levels between producer, non-producer and defective proviruses regardless of the integration orientation of the provirus with regard to the host gene (Extended Data Fig. 3g,h).

Distinct cell survival and interferon signaling in NSV

Cell survival signaling has been linked to HIV-1 persistence, especially in latently infected CD4⁺ T cells^{42,43}. To understand the association between cell signaling and NSV, we compared the CD4⁺ T cell transcriptomic features between the NSV group (*N* = 8) and a subgroup of the ART-suppressed individuals (*N* = 5) with available RNA sequencing

(RNA-seq) data^{44,45}. Compared with the ART-suppressed individuals, participants with NSV had 265 upregulated genes and 427 downregulated genes in total CD4⁺ T cells (adjusted P value (P_{adj}) < 0.1, Fig. 4a). Among these differentially expressed genes (DEGs), Gene Set Enrichment Analysis (GSEA) revealed enrichment of pathways related to HIV-1 infection, HIV-1 life cycle and transcription in the NSV group (Fig. 4b). CD4⁺ T cells from the NSV group exhibited enrichment in oxidative phosphorylation and apoptosis-related signals (Fig. 4b top and Extended Data Fig. 4a). Specifically, CD4⁺ T cells from participants with NSV appeared to be primed for survival via downregulation of pro-apoptotic genes and upregulation of genes associated with anti-apoptotic pathways, including proteasome-related genes (for example, *PSMB1*, *PSMB2* and *PSMD14*), ubiquitination-related genes, and oncogenes such as *PIK3CA* and *PIK3RI* (Fig. 4c,d)^{46–49}.

Transcriptomic analysis also highlighted differences in the immune responses between NSV and ART-suppressed individuals. Participants with NSV demonstrated upregulation of immunosuppression-related genes in total CD4⁺ T cells, including *CTLA4* and *FOXP3* (Fig. 4a), pointing to an enrichment of the RUNX1-related pathway, which is associated with attenuation in antiviral and interferon (IFN) signaling through FOXP3 binding^{50,51}. In fact, both IFN- α/β and IFN- γ signaling were enriched in ART-suppressed individuals (Fig. 4b bottom and Extended Data Fig. 4b,c). IFN signaling plays a pivotal role in HIV-1 pathogenesis by inducing viral restriction factors, causing depletion of CD4⁺ T cells, and regulating systemic immune activation⁵². These results may point towards potential defects in immune-mediated control of a highly active HIV-1 reservoir as a contributing factor for NSV.

Absence of immune activation and evidence of HLA escape in NSV

We next assessed the impact of NSV on inflammation and immune activation. Levels of 12 plasma soluble markers of inflammation were compared between participants with NSV and ART-suppressed participants. Participants with NSV demonstrated lower IL-10 and elevated IL-6, but no significant differences in levels of C-reactive protein, sCD14 and sCD163 compared with ART-suppressed individuals (Extended Data Fig. 5). Of note, the older age of the participants with NSV could be playing a role in the higher IL-6 levels found in the participants with NSV compared with the ART-suppressed participants⁵³. Levels of activated HLA-DR⁺CD38⁺ CD4⁺ and CD8⁺ T cells were compared among participants with NSV, ART-suppressed participants and a cohort of historical VCs, who can achieve immune-mediated control of HIV-1 replication without ART⁵⁴. Despite similar levels of viremia to the VCs (Extended Data Fig. 6a), participants with NSV had substantially lower levels of CD8⁺ T cell activation compared with VCs and comparable levels compared with ART-suppressed individuals (Fig. 5a). There were no differences in the intensity and frequency of CD4-expressing cells between groups (Extended Data Fig. 6b,c).

HIV-specific CD8⁺ T cells, which recognize viral peptides presented in complex with HLA Class-I (HLA-A, HLA-B, and HLA-C), are thought to be one of the key mediators of viral control^{55,56}. Among NSV, ART-suppressed and VC participants, the magnitude of effector HLA-restricted HIV-specific T cell activity and proliferative HIV-specific CD8⁺ T cells aligned with overall CD8⁺ T cell activation. VCs had significantly greater HIV-specific CD8⁺ T cell responses by IFN- γ ELISpot and T cell proliferation assays in comparison with both participants with NSV and ART-suppressed participants (Fig. 5b,c). In VCs, elevated HIV-specific CD8⁺ T cell responses were detected against HIV-1 Gag, Pol, Env and Nef peptides, with the most robust responses towards Gag (Extended Data Fig. 7). Of note, the relatively muted HIV-specific CD8⁺ T cell response in NSV was paired with a modestly higher average number of HLA-adapted (escape) mutations⁵⁷ in producer proviruses compared with non-producer ($P = 0.04$) and a substantially higher escape burden compared with defective proviruses adjusted for proviral length ($P = 0.001$, Fig. 5d). After normalizing for the size of

each HIV-1 gene, *nef* showed significantly higher numbers of adapted and possible adapted mutations compared with other HIV-1 genes (Fig. 5e and Extended Data Fig. 8). Adapted and possible adapted mutations in HIV-1 genomes in both producers and non-producers highly correlated with CD8⁺ T cell IFN- γ release but not with proliferation (Fig. 5f,g), suggesting a relationship between effector HIV-specific CD8⁺ T cell responses with relatively decreased functionality (that is, proliferation) and subsequent emergence of mutations within proviral clones. Specifically, the number of *nef* adapted and possible adapted mutations in producer proviruses was strongly correlated with CD8⁺ T cell IFN- γ release in NSV ($r = 0.94$, $P = 0.02$, Fig. 5f,h). Adapted and possible adapted mutations in *pol* in producer proviruses also significantly correlated with total CD8⁺ T cell activity ($r = 0.84$, $P = 0.04$, Fig. 5i) and may represent immune-driven viral escape mutations that accumulated before ART initiation.

A subset of producers has deletions in the 5' leader region

Our sequencing revealed that NSV is largely composed of one or two clonal populations that remain stable over time, which is consistent with high-level viral production from a large, clonally expanded population of HIV-1-infected cells as the primary driver of NSV, rather than ongoing viral replication on ART. Since NSV need not be composed of infectious virus, we evaluated producer proviruses for potential replication defects, including deletions in the 5' PSI packaging element⁵⁸. In 38% (3/8) of participants with NSV, we observed that producer proviruses harbored deletions in the 5' end of HIV-1 genome (Extended Data Fig. 9, black boxes). These deletions, which encompassed 22, 15 and 41 nucleotides in participants LV4, LV7 and LV8, respectively, all occurred within SL1 and SL2 elements, ending at the same location within the splice donor site. Plasma HIV-1 RNA sequencing of the 5' leader/*gag* region of HIV-1 was performed to confirm the presence of these 5' defects within the plasma HIV-1 RNA sequences. To evaluate whether these proviruses were infectious, viral outgrowth assays (VOAs) were performed using a transwell system with participant CD4⁺ T cells (LV4, LV7 and LV8; LV2, LV5 and LV9 served as controls) in the bottom chamber and MOLT-4/CCR5 cells in the upper chamber. HIV-1 DNA from the MOLT-4 cells was extracted and subjected to MIP-seq analysis. None of the proviruses with 5' deletions was isolated in the VOA. Producer provirus was isolated from the VOA for LV9 (Fig. 2a and Extended Data Fig. 10). Non-producer proviruses were isolated from the VOA for LV2, LV5 and LV8 (Fig. 2a)⁵⁸.

Discussion

In this study, we have conducted a comprehensive assessment of NSV in eight participants and have provided insight into ART-independent factors implicated in HIV-1 suppression and persistence. Our results indicate that suboptimal ART adherence and drug resistance do not appear to be the drivers of non-suppressible viremia. In these participants, our data suggest that NSV is driven instead by the critical intersection of viral and host immune factors. Specifically, the NSV phenotype was highlighted by the presence of large, clonally expanded reservoirs of proviruses frequently harboring immune escape mutations (and/or defects in the 5' leader region), integrated in transcriptionally permissive chromosomal regions, within CD4⁺ T cells primed for survival, and in an environment of muted HIV-specific T cell responses (Supplementary Fig. 3).

In one of the first in-depth reservoir studies of NSVs, Halvas et al. reported that NSV is composed largely of identical populations of plasma viruses that arise from the expansion of HIV-1-infected CD4⁺ T cell clones, which they termed replicones¹. However, most prior studies sequenced relatively short fragments of viral RNA, which can overestimate the clonality of plasma sequences. Our plasma HIV-1 RNA sequencing assay was combined with an ultrasensitive RNA extraction process for 6.7 kb *pol-env* RNA-seq (Extended Data Fig. 10).




Fig. 4 | Transcriptomic analysis of CD4⁺ T cells from participants with NSV. **a**, Volcano plot shows DEGs in participants with NSV versus ART-suppressed individuals. Red and blue colors highlight differential statistical significance. Adjustments were made for multiple comparisons using the Benjamini–Hochberg method built in the DESeq2 package. **b**, Normalized enrichment score (NES) reflects the degree to which a set of genes is overrepresented among genes that are differentially expressed between participants with

NSV and ART-suppressed control participants. Bar plot represents genes positively (red) and negatively (blue) correlated pathways. Adjustments were made for multiple comparisons using the Benjamini–Hochberg method. **c**, Genes related to apoptosis/cell death enriched in participants with NSV. **d**, Comparison of anti-apoptotic and pro-apoptotic gene transcription levels between NSV and ART-suppressed control group. Two-sided Mann–Whitney *U* tests were used for comparisons. TPM, transcripts per million.

These results confirm that, in our cohort, NSV is composed primarily of one to two large plasma viral clones that composed >70% of plasma viruses. The role of these viral clones as the primary driver of NSV was confirmed across multiple longitudinal time points, which failed to reveal evidence of plasma viral sequence changes and evolution. For all of the participants with NSV, we were able to identify exact proviral sequence matches for the large plasma clones. We found that the size of the producer proviral reservoir was significantly larger than either the size of the non-producer proviruses in participants with NSV or intact proviruses in ART-suppressed participants, although admittedly with a broad distribution in size of the producer proviral reservoir. The large size of these producer proviral reservoirs and their ability to maintain NSV over years highlight the relative stability of this reservoir. These results and the presence of NSV over many years suggests an intrinsic ability of these HIV-infected cells to maintain prolonged survival and/or proliferate. Prior studies have reported that CD4⁺ T cells modulating key pro- and anti-apoptotic pathways can maintain survival of HIV-infected cells, drive clonal expansion and guard against CTLs^{43,59}. Compared with ART-suppressed participants, CD4⁺ T cells in participants with NSV demonstrated transcriptional upregulation

of anti-apoptotic pathways and downregulation of pro-apoptotic pathways. While transcriptional analysis was not isolated to producer cells alone, these results suggest that the CD4⁺ T cell environment in participants with NSV is primed for survival. Lymphoid clonal hematopoiesis (L-CH) refers to the expansion of hematopoietic stem cell clones in relation to age that is triggered by the acquisition of specific point mutations or chromosomal alterations in somatic cells. Recent studies have revealed the presence of L-CH in conditions such as autoimmunity or immunodeficiency, and the role of L-CH in NSV should be studied in the future⁶⁰.

Using the MIP-seq assay³⁹, we were able to identify the location of HIV-1 integration sites in host chromosomes for 11 producer, 21 intact non-producer and 44 defective proviruses across participants with NSV. HIV-1 integration is known to favor active chromatin, and proximity to activating epigenetic marks can modulate proviral gene expression and hence the fate of the resident provirus and infected cell^{61,62}. We and others have reported that with prolonged ART, intact proviruses are more likely to be found in non-genic regions, in opposite orientation from the host gene and more distant from accessible chromosomal regions that highlight the selection of intact proviruses integrated into




Fig. 5 | HIV-specific CD8⁺ T cell response and HLA class I escape mutations. **a**, Frequency of HLA-DR⁺ CD38⁺ in CD4⁺ and CD8⁺ T cells. **b**, HIV-specific CD8⁺ T cell ELISPOT responses in NSV, ART-suppressed, and viremic controller (VC) cohorts. SFU, spot forming units. **c**, HIV-specific CD8⁺ T cell proliferation responses. Medians and interquartile ranges are shown in the violin plots. Two-sided Mann–Whitney *U* test was used. **d**, Average numbers of adapted and possible adapted HLA escape mutations per base across producer, non-producer and defective proviral sequences. Wilcoxon matched-pairs signed-rank testing was used. **e**, Average number of mutations per base pair for each HIV-1 gene in producer proviruses (*n* = 8). Two-sided pairwise Wilcoxon signed-rank test was used, and adjustments were made for multiple comparisons using the

Benjamini–Hochberg method. In the boxplots, center lines indicated median, box limits indicated upper and lower quartiles and whiskers indicated minimal and maximal values. **f**, Spearman correlation between adapted and possible adapted mutations in different HIV-1 genes in producer proviruses alongside CD8⁺ T cell proliferation activity and percent intact provirus. **g**, Spearman correlation between adapted and possible adapted mutations in three proviral classes and CD8⁺ T cell activity (ELISPOT). **h, i**, Spearman correlation between CD8⁺ T cell activity (ELISPOT) versus average adapted and possible adapted mutations in *nef* (**h**) and *pol* (**i**) in producer proviruses (normalized by gene size). Spearman correlation test was used. NS, not significant; **P* < 0.05, ***P* < 0.01.

regions of deep latency⁶³. In participants with NSV, we found enrichment of integration in chromosome 19, which is distinctively enriched for gene density^{64,65}. We also demonstrated that producer proviruses were located in regions enriched in certain epigenetic characteristics,

including a greater number of H3K36me3 histone peaks, which are associated with a transcriptionally permissive chromosomal regions and elevated proviral expression³⁸. A higher number of H3K36me3 peaks surrounding the producer provirus was also strongly associated

with higher plasma viral load composed of that clone. These results show that the location of HIV-1 proviral integration in the host genome is a determinant of its eventual fate and align with emerging evidence that the processes of entering and exiting proviral transcriptional latency are influenced by epigenetic mechanisms, making them potentially susceptible to pharmacological interventions.

We found that the persistence of non-suppressible viremia occurred in an environment of relatively muted inflammation and immune activation, featuring the downregulation of IFN response genes, generally low levels of soluble inflammatory markers, and no significant increase in HIV-specific CD8⁺ T cell responses compared with ART-suppressed individuals. IFN plays a vital role in the innate host antiviral response and contributes to the suppression of HIV-1 viremia⁶⁶. Compared with ART-suppressed participants, participants with NSV significantly downregulated transcription of multiple genes involved in the IFN-response pathway by bulk CD4 transcriptomic analysis. These include IFN regulatory factors 3 and 7 (*IRF3* and *IRF7*), *OAS1* and other genes known to be part of critical circuits for stimulating host antiviral immune responses^{67,68}. While transcriptomic analysis was performed only on bulk CD4 cells, the results do provide some intriguing signals related to latency reversal and cellular survival. For example, BIRC2 is an inhibitor of apoptosis protein (IAP), which suppresses HIV-1 transcription and depletion of BIRC2 can lead to HIV-1 latency reversal⁶⁹. Participants with NSV downregulated the expression of TNFRSF14, the receptor for the LIGHT/TNFSF14 ligand, which binds BIRC2 (ref. 70). Inhibitors of LIGHT/TNFSF14 are being developed for cancer immunotherapy⁷¹ and could be assessed for HIV-1 latency reversal potential. In addition, participants with NSV were found to upregulate expression of PIK3R1 and PIK3CA (among other anti-apoptotic genes), which help encode phosphatidylinositol 3-kinase, an enzyme that promotes cellular survival through activation of Akt. Whether the use of phosphatidylinositol 3-kinase inhibitors could contribute to clearing HIV-infected cells should also be explored^{72,73}.

Heightened HIV-specific CD8⁺ T cell responses occur with HIV-1 viremia, which is critical to suppress the HIV-1 reservoir⁷⁴. Thus, we were surprised to find a relatively muted CD8⁺ T cell response, with no significant differences noted in HLA-restricted HIV-specific CD8⁺ T cell activity and proliferation between the individuals with NSV and ART-suppressed individuals, and significantly lower levels than seen in VCs with similar levels of viremia. Together, the transcriptomic, soluble inflammatory and T cell data demonstrated that NSV appears to be uncoupled with immune activation. There are several possible explanations for the relatively low levels of HIV-specific T cell responses. First, producer proviruses harbored higher frequencies of adaptive HLA escape mutations, which may explain the suboptimal induction of HIV-specific CD8⁺ T cell activity due to a loss of antigen recognition⁷⁵. Of note, there was an enrichment of HLA-escape mutations in *nef*, which may be particularly immunogenic as previous studies have reported that the strength of the Nef-specific T cell activity is linked with the size of the HIV-1 reservoir⁷⁶. Another potential mechanism of immune escape may be the contribution of defective virions to NSV. In 38% (three of eight) of our individuals with NSV, we detected deletions in the 5' leader sequence of the HIV-1 genome. None of these sequences was recovered using the VOA, suggesting these proviruses may be replication defective. The 5'-untranslated leader contains several structural motifs that are involved in multiple steps of HIV-1 replication. The deletions are present in the psi (Ψ) element, which is a highly structured RNA sequence with four hairpin stem loops and a strong affinity for the nucleocapsid domain of the viral Gag protein. Genome packaging during virus assembly and reverse transcription during the subsequent round of infection are some known functions of the 5' leader region^{77,78}. A recent study by White et al. described four participants with NSV with apparent defects in the 5' leader sequence⁵⁸. These defects generally spanned the major splice donor site and resulted in the creation of non-functional virions lacking the envelope glycoprotein. Interestingly, the

5' leader sequence deletions in our participants with NSV spanned the same region and, in fact, LV4 shares the same 22-base deletion that was detected in three participants by White et al. The detection of 5' leader defects at high frequencies across multiple cohorts suggests a selective advantage of these proviruses in conferring the NSV phenotype, potentially by maintaining a plasma viral load in the absence of HIV-1 replication and/or the ability of Env-deleted virions to escape from host immune surveillance⁷⁹. It has also become increasingly clear that cellular metabolism represents a crucial regulator of T cell activation and response. Additional studies are also needed to assess the role of metabolic programs and pathways, such as altered glutaminolysis and glycolysis, in suppressing T cell function in participants with NSV⁸⁰.

In addition to the previously noted limitations, the small size of the NSV cohort analyzed in this study is a key limitation. Also, we estimated proviral reservoir size by near-full-length proviral sequencing. This could lead to some underestimation of the actual reservoir size, although other methods for reservoir quantification (for example, intact proviral DNA assay) may overestimate the size⁸¹. Future studies will need to investigate the size of producer proviruses within tissue reservoirs. We found that the peripheral blood reservoir of HIV-infected CD4⁺ T cells contributing to NSV can differ dramatically between participants with NSV. It is possible that NSV-generating CD4⁺ T cells are also distributed within anatomical tissue compartments^{82,83}, especially for those participants with NSV with a relatively small producer proviral reservoir size in the peripheral blood. Prior studies have shown that Gag- or CMV-specific antigens can drive the expansion of certain HIV-infected cellular clones³². Additional studies are needed to delineate which antigens might be playing a role in the expansion of the producer proviruses. Neutralizing antibody responses can also suppress viremia⁸⁴ and evaluation of the humoral immune responses are indicated, although prior studies suggest that some NSV is resistant to autologous neutralizing antibodies⁸⁵. The lack of viral evolution and ongoing viral replication on longitudinal phylogenetic analysis may explain why ART intensification has not led to virologic efficacy in those with NSV. It is unknown whether newer ARVs, including drugs with potential immunomodulatory properties (for example, fostemsavir⁸⁶) could provide additional virologic benefit.

In this study, we identified critical host and viral mediators of NSV that represent potential targets to disrupt HIV-1 persistence and promote viral silencing. Importantly, ultrasensitive HIV-1 viral load assays can detect residual low levels of HIV-1 viremia in the vast majority of PWH, even on apparently suppressive ART⁸⁷. Previous studies have reported that such residual viremia is largely composed of drug-sensitive virus¹⁶ and relatively homogeneous viral populations¹⁸. Thus, we believe it is likely that the mechanisms behind NSV that we describe here are present to some extent in most, if not all, of PWH. Achieving an in-depth understanding of the mechanisms behind NSV may provide insight on strategies for HIV-1 reservoir eradication applicable to all PWH.

Online content

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-023-02611-1>.

References

1. Halvas, E. K. et al. HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus. *J. Clin. Invest.* **130**, 5847–5857 (2020).
2. Laprise, C., de Pokomandy, A., Baril, J. G., Dufresne, S. & Trottier, H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. *Clin. Infect. Dis.* **57**, 1489–1496 (2013).

3. Ryscavage, P., Kelly, S., Li, J. Z., Harrigan, P. R. & Taiwo, B. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. *Antimicrob. Agents Chemother.* **58**, 3585–3598 (2014).
4. Redd, A. D. et al. ART adherence, resistance, and long-term HIV viral suppression in postpartum women. *Open Forum Infect. Dis.* **7**, ofaa346 (2020).
5. Dharan, N. J. & Cooper, D. A. Long-term durability of HIV viral load suppression. *Lancet HIV* **4**, e279–e280 (2017).
6. Fleming, J. et al. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy. *AIDS* **33**, 2005–2012 (2019).
7. Prendergast, A. J. et al. The impact of viraemia on inflammatory biomarkers and CD4⁺ cell subpopulations in HIV-infected children in sub-Saharan Africa. *AIDS* **35**, 1537–1548 (2021).
8. Castillo-Mancilla, J. R. et al. Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV. *Open Forum Infect. Dis.* **8**, ofab463 (2021).
9. Li, J. Z. et al. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. *Antimicrob. Agents Chemother.* **56**, 5998–6000 (2012).
10. Gunthard, H. F. et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. *J. Virol.* **72**, 2422–2428 (1998).
11. Martinez-Picado, J. et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. *Proc. Natl Acad. Sci. USA* **97**, 10948–10953 (2000).
12. Elvstam, O. et al. Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European Multicenter Cohort. *Clin. Infect. Dis.* **76**, 25–31 (2023).
13. Boillat-Blanco, N. et al. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study. *Antivir. Ther.* **20**, 165–175 (2015).
14. Vancoillie, L. et al. Longitudinal sequencing of HIV-1 infected patients with low-level viremia for years while on ART shows no indications for genetic evolution of the virus. *Virology* **510**, 185–193 (2017).
15. Podsadecki, T. J., Vrijens, B. C., Tousset, E. P., Rode, R. A. & Hanna, G. J. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. *J. Infect. Dis.* **196**, 1773–1778 (2007).
16. Hermankova, M. et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. *JAMA* **286**, 196–207 (2001).
17. Havlir, D. V. et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. *JAMA* **286**, 171–179 (2001).
18. Bull, M. E. et al. Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation. *AIDS* **32**, 1389–1401 (2018).
19. Li, J. Z. et al. Impact of pre-existing drug resistance on risk of virological failure in South Africa. *J. Antimicrob. Chemother.* **76**, 1558–1563 (2021).
20. Castillo-Mancilla, J. R. et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. *AIDS Res Hum. Retroviruses* **29**, 384–390 (2013).
21. Yager, J. et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following tenofovir alafenamide: the TAF-DBS Study. *J. Acquir Immune Defic. Syndr.* **84**, 323–330 (2020).
22. Castillo-Mancilla, J. et al. Emtricitabine-triphosphate in dried blood spots as a marker of recent dosing. *Antimicrob. Agents Chemother.* **60**, 6692–6697 (2016).
23. Coyle RP et al. Tenofovir diphosphate in dried blood spots in persons with HIV taking tenofovir alafenamide as digital pills: preliminary data from the QUANTI-TAF Study. In *International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs*. (2022).
24. Frasca, K. et al. Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy. *J. Antimicrob. Chemother.* **74**, 1395–1401 (2019).
25. Morrow, M. et al. Predictive value of tenofovir diphosphate in dried blood spots for future viremia in persons living with HIV. *J. Infect. Dis.* **220**, 635–642 (2019).
26. Morrow, M. et al. Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence. *AIDS* **35**, 1949–1956 (2021).
27. Schroder, A. R. et al. HIV-1 integration in the human genome favors active genes and local hotspots. *Cell* **110**, 521–529 (2002).
28. Wang, G. P., Ciuffi, A., Leipzig, J., Berry, C. C. & Bushman, F. D. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. *Genome Res.* **17**, 1186–1194 (2007).
29. Francis, A. C. et al. HIV-1 replication complexes accumulate in nuclear speckles and integrate into speckle-associated genomic domains. *Nat. Commun.* **11**, 3505 (2020).
30. Maldarelli, F. et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. *Science* **345**, 179–183 (2014).
31. Wang, Z. et al. Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. *Proc. Natl Acad. Sci. USA* **115**, E2575–E2584 (2018).
32. Simonetti, F. R. et al. Antigen-driven clonal selection shapes the persistence of HIV-1-infected CD4⁺ T cells in vivo. *J. Clin. Invest.* **131**, e145254 (2021).
33. Coffin, J. M. et al. Integration in oncogenes plays only a minor role in determining the in vivo distribution of HIV integration sites before or during suppressive antiretroviral therapy. *PLoS Pathog.* **17**, e1009141 (2021).
34. Bedwell, G. J., Jang, S., Li, W., Singh, P. K. & Engelman, A. N. rigrag: high-resolution mapping of genic targeting preferences during HIV-1 integration in vitro and in vivo. *Nucleic Acids Res.* **49**, 7330–7346 (2021).
35. Lian, X. et al. Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy. *Cell Host Microbe* **31**, 83–96.e85 (2023).
36. Sun, W. et al. Phenotypic signatures of immune selection in HIV-1 reservoir cells. *Nature* **614**, 309–317 (2023).
37. Einkauf, K. B. et al. Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. *Cell* **185**, 266–282.e215 (2022).
38. Vansant, G. et al. The chromatin landscape at the HIV-1 provirus integration site determines viral expression. *Nucleic Acids Res.* **48**, 7801–7817 (2020).
39. Einkauf, K. B. et al. Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. *J. Clin. Invest.* **129**, 988–998 (2019).
40. Kundaje, A. et al. Integrative analysis of 111 reference human epigenomes. *Nature* **518**, 317–330 (2015).
41. Sun, Z. et al. H3K36me3, message from chromatin to DNA damage repair. *Cell Biosci.* **10**, 9 (2020).
42. Ren, Y. et al. Selective BCL-X(L) antagonists eliminate infected cells from a primary-cell model of HIV latency but not from ex vivo reservoirs. *J. Virol.* **95**, e0242520 (2021).
43. Ren, Y. et al. BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo. *J. Clin. Invest.* **130**, 2542–2559 (2020).

44. Etemad, B. et al. HIV post-treatment controllers have distinct immunological and virological features. *Proc. Natl Acad. Sci. USA* **120**, e2218960120 (2023).
45. Wedrychowski, A. et al. Transcriptomic signatures of human immunodeficiency virus post-treatment control. *J. Virol.* **97**, e0125422 (2023).
46. Philp, A. J. et al. The phosphatidylinositol 3'-kinase p85 α gene is an oncogene in human ovarian and colon tumors. *Cancer Res.* **61**, 7426–7429 (2001).
47. Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. *Cancer Cell* **7**, 561–573 (2005).
48. Lata, S., Mishra, R. & Banerjee, A. C. Proteasomal degradation machinery: favorite target of HIV-1 proteins. *Front. Microbiol.* **9**, 2738 (2018).
49. Satou, Y. et al. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. *Leukemia* **18**, 1357–1363 (2004).
50. Hu, Y. et al. RUNX1 inhibits the antiviral immune response against influenza A virus through attenuating type I interferon signaling. *Virology* **19**, 39 (2022).
51. Ono, M. et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. *Nature* **446**, 685–689 (2007).
52. Utay, N. S. & Douek, D. C. Interferons and HIV infection: the good, the bad, and the ugly. *Pathog. Immun.* **1**, 107–116 (2016).
53. Wyczalkowska-Tomasik, A., Czarkowska-Paczek, B., Zielenkiewicz, M. & Paczek, L. Inflammatory markers change with age, but do not fall beyond reported normal ranges. *Arch. Immunol. Ther. Exp.* **64**, 249–254 (2016).
54. Saez-Cirion, A. et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. *Proc. Natl Acad. Sci. USA* **104**, 6776–6781 (2007).
55. Collins, D. R., Gaiha, G. D. & Walker, B. D. CD8⁺ T cells in HIV control, cure and prevention. *Nat. Rev. Immunol.* **20**, 471–482 (2020).
56. Cartwright, E. K. et al. CD8⁺ lymphocytes are required for maintaining viral suppression in HIV-infected macaques treated with short-term antiretroviral therapy. *Immunity* **45**, 656–668 (2016).
57. Warren, J. A. et al. The HIV-1 latent reservoir is largely sensitive to circulating T cells. *eLife* **9**, e57246 (2020).
58. White, J. A. et al. Clonally expanded HIV-1 proviruses with 5'-leader defects can give rise to nonsuppressible residual viremia. *J. Clin. Invest.* **133**, e165245 (2023).
59. Kuo, H.-H. et al. Anti-apoptotic protein BIRC5 maintains survival of HIV-1-infected CD4⁺ T Cells. *Immunity* **48**, 1183–1194.e1185 (2018).
60. Zekavat, S. M. et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. *Nat. Med.* **27**, 1012–1024 (2021).
61. Janssens, J., De Wit, F., Parveen, N. & Debyser, Z. Single-Cell Imaging Shows That the Transcriptional State of the HIV-1 Provirus and Its Reactivation Potential Depend on the Integration Site. *mBio* **13**, e0000722 (2022).
62. Vansant, G. et al. The chromatin landscape at the HIV-1 provirus integration site determines viral expression. *Nucleic Acids Res.* **48**, 7801–7817 (2020).
63. Einkauf, K. B. et al. Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. *J. Clin. Invest.* **129**, 988–998 (2019).
64. Grimwood, J. et al. The DNA sequence and biology of human chromosome 19. *Nature* **428**, 529–535 (2004).
65. Singh, P.K., Bedwell, G.J. & Engelman, A.N. Spatial and Genomic Correlates of HIV-1 Integration Site Targeting. *Cells* **11**(2022).
66. Rout, S. S., Di, Y., Dittmer, U., Sutter, K. & Lavender, K. J. Distinct effects of treatment with two different interferon-alpha subtypes on HIV-1-associated T-cell activation and dysfunction in humanized mice. *AIDS* **36**, 325–336 (2022).
67. Soper, A. et al. Type I Interferon Responses by HIV-1 Infection: Association with Disease Progression and Control. *Front Immunol.* **8**, 1823 (2017).
68. Doehle, B. P., Hladik, F., McNevin, J. P., McElrath, M. J. & Gale, M. Jr. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. *J. Virol.* **83**, 10395–10405 (2009).
69. Pache, L. et al. BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. *Cell Host Microbe* **18**, 345–353 (2015).
70. Kuai, J. et al. Endogenous association of TRAF2, TRAF3, cIAP1, and Smac with lymphotoxin beta receptor reveals a novel mechanism of apoptosis. *J. Biol. Chem.* **278**, 14363–14369 (2003).
71. Skeate, J. G. et al. TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy. *Front Immunol.* **11**, 922 (2020).
72. Pasquereau, S. & Herbein, G. CounterAKTing HIV: Toward a “Block and Clear” Strategy? *Front Cell Infect. Microbiol.* **12**, 827717 (2022).
73. Kim, Y., Anderson, J. L. & Lewin, S. R. Getting the “Kill” into “Shock and Kill”: Strategies to Eliminate Latent HIV. *Cell Host Microbe* **23**, 14–26 (2018).
74. Chun, T. W. et al. Suppression of HIV replication in the resting CD4⁺ T cell reservoir by autologous CD8⁺ T cells: implications for the development of therapeutic strategies. *Proc. Natl Acad. Sci. USA* **98**, 253–258 (2001).
75. Gulzar, N. & Copeland, K. F. CD8⁺ T-cells: function and response to HIV infection. *Curr. HIV Res.* **2**, 23–37 (2004).
76. Thomas, A. S. et al. T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy. *PLoS Pathog.* **13**, e1006629 (2017).
77. Lawrence, D. C., Stover, C. C., Noznitsky, J., Wu, Z. & Summers, M. F. Structure of the Intact Stem and Bulge of HIV-1 Ψ -RNA Stem-Loop SL1. *J. Mol. Biol.* **326**, 529–542 (2003).
78. Durand, S. et al. Quantitative analysis of the formation of nucleoprotein complexes between HIV-1 Gag protein and genomic RNA using transmission electron microscopy. *J. Biol. Chem.* **298**, 101500 (2022).
79. van Bel, N., Das, A. T., Cornelissen, M., Abbink, T. E. & Berkhout, B. A short sequence motif in the 5' leader of the HIV-1 genome modulates extended RNA dimer formation and virus replication. *J. Biol. Chem.* **289**, 35061–35074 (2014).
80. Chapman, N. M., Boothby, M. R. & Chi, H. Metabolic coordination of T cell quiescence and activation. *Nat. Rev. Immunol.* **20**, 55–70 (2020).
81. White, J. A. et al. Measuring the latent reservoir for HIV-1: Quantification bias in near full-length genome sequencing methods. *PLoS Pathog.* **18**, e1010845 (2022).
82. Bailey, J. R. et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4⁺ T cells. *J. Virol.* **80**, 6441–6457 (2006).
83. De Scheerder, M. A. et al. HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs. *Cell Host Microbe* **26**, 347–358.e347 (2019).
84. Cizmeci, D., et al. Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. *Elife* **10**(2021).
85. White, J.A., et al. Clonally expanded HIV-1 proviruses with 5'-Leader defects can give rise to nonsuppressible residual viremia. *J Clin Invest* (2023).
86. Richard, J. et al. Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120. *Cell Chem. Biol.* **30**, 540–552.e546 (2023).
87. Palmer, S. et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. *Proc. Natl Acad. Sci. USA* **105**, 3879–3884 (2008).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this

article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ²Valley Health System, Las Vegas, NV, USA. ³Beijing Friendship Hospital Pinggu Campus, Capital Medical University, Beijing, China. ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. ⁵University of Pittsburgh, Pittsburgh, PA, USA. ⁶Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. ⁷Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. ⁸Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. ⁹Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, USA. ¹⁰Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ¹¹Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA. ¹²Basic Science Program, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD, USA. ¹³Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. ¹⁴Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada. ¹⁵British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. ¹⁶Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. ✉e-mail: jli@bwh.harvard.edu

Methods

Participants

In an observational study, we enrolled 8 ART-treated participants with three or more HIV-1 RNA levels between 40 and 1,000 copies ml⁻¹ over 24 months of whom 7 (88%) were men and compared them with a historic cohort of 11 ART-suppressed participants, of whom 5 (71%) were men, with HIV-1 with similar demographic and CD4 counts. Sex and/or gender of participants was determined on the basis of self-report. A participant with non-suppressible viremia enrolled in the HIV Eradication and Latency (HEAL) cohort, a biorepository of Brigham and Women's Hospital, was included as a part of eight NSVs. The NSV samples were taken from different time points, enabling us to study these participants longitudinally (Fig. 1 and Extended Data Fig. 1). The ART-suppressed comparators included 11 participants from the AIDS Clinical Trials Group (ACTG) and 7 participants from the Ragon Institute of Massachusetts General Hospital, the Massachusetts Institute of Technology and Harvard. Both ART-suppressed comparator groups were well matched with the participants with NSV by CD4 count. A cohort of VCs not on ART with similar viral loads to the participants with NSV was also included for the T cell analysis. All study participants provided written informed consent. The study was approved by the Mass General Brigham Institutional Review Board.

ARV drug level testing

For plasma ARV testing, samples were sent to the infectious disease pharmacokinetics lab at the University of Florida. Testing was performed for darunavir and dolutegravir by liquid chromatography with tandem mass spectrometry. For DBS ARV testing, 25 ml of whole blood were spotted five times onto Whatman 903 protein saver cards, as previously described^{21,82}. After spotting, cards were allowed to dry at room temperature for at least 3 h (as long as overnight), after which they were stored at -80 °C until analyzed. TFV-DP and FTC-TP were quantified from two 7-mm punches extracted with 2 ml of methanol:water to create a lysed cellular matrix using a previously validated method that was adapted and validated for tenofovir alafenamide-containing regimens. The assay was linear and ranged from 25 to 6,000 fmol per sample for TFV-DP and from 0.1 to 200 pmol per sample for FTC-TP^{21,88}.

DNA isolation and HIV reservoir quantification

DNA extractions were carried out from PBMCs using the QIAamp DNA Micro Kit (cat. no. 56304), and the quantification of DNA was performed with Nanodrop (Applied Biosystems, Thermo Fisher). To estimate the size of the reservoir, we analyzed near-full-length proviral sequences as described below.

Near-full-length proviral sequencing, sequence alignments, quality control and neighbor joining analyses

Extracted DNA was endpoint-diluted and subjected to near full-length sequencing (NFL-seq), as previously described⁶³. We classified our sequences into intact and different classes of defective proviruses (for example, 5'-defect, deletion, hypermutation and inversion) using a published proviral intactness pipeline⁸⁸. Briefly, after aligning to HXB2, we called our sequences as large deleterious deletions if they had a <8,000-bp amplicon size, out-of-frame indels, premature/lethal stop codons, internal inversions or packaging signal deletions (≥15 bp). The Los Alamos National Laboratory HIV Sequence Database Hypermut 2 program was used to identify the existence or nonexistence of hypermutations linked to APOBEC-3G/3F. Sequences of the virus that did not have any of the mutations listed earlier were categorized as 'genome-intact' sequences. Using MAFFT v7.2.0, we aligned the sequences and utilized MEGA 6 to deduce neighbor joining trees. We called those proviruses with an exact match with plasma sequences 'producers' and intact proviruses without matching plasma sequences 'non-producers'.

Plasma HIV-1 RNA sequencing

We sequenced plasma HIV RNA as previously described.⁸⁹ Extracted RNA was diluted to single viral genome levels to meet the criteria of single-genome sequencing of having no more than one template in each well, theoretically no more than 25% of wells being positive for HIV. Primers were designed to amplify *pol-env*, a 6.7-kb region (Supplementary Data 1). The amplification reaction was performed using 0.5 µl primers (10 µmol), 1 µl (10 mmol) MgSO₄, 1 µl (10 mmol) dNTPs and 1 U Platinum Taq Polymerase (Invitrogen) in 25 µl total volume. Polymerase chain reaction conditions consisted of a denaturation step at 94 °C for 2 min, followed by 30 cycles of 30 s at 94 °C, 30 s at 56 °C, 90 s at 68 °C and 10 min at 68 °C. Products underwent Illumina barcoded library construction and MiSeq sequencing. Amplicons were assembled using the UltraCycler v1.0 automated de novo sequence assembly to generate a continuous fragment. Plasma sequences that were within one to two nucleotides of the near-full-length proviral sequence was considered part of the clonal cluster. We counted the total number of plasma sequences in each clone and divided them by all plasma sequences that we had generated. Then we multiplied the ratio with the plasma viral load to determine the contribution of each clone for plasma viral load, which we termed the plasma clone viral load.

For each sequence, the GSS versus the participants' ART regimen was calculated using the Stanford HIV database drug resistance scoring system. The Stanford HIV database provides a weighted penalty score for the effect of every resistance mutation and antiretroviral medication with 0 if there is no expected effect to 60 for high-level resistance. For each sequence, the estimated level of resistance for each antiretroviral medication (ARV) was determined by adding all of the penalty scores for each of the drug resistance mutations present. The GSS of each ARV was defined as the following: 1 (Stanford penalty score 0–9), 0.75 (Stanford penalty score 10–14), 0.5 (Stanford penalty score 15–29), 0.25 (Stanford penalty score 30–59) and 0 (Stanford penalty score ≥60). The GSS for the sequence was the sum of the GSS for each ARV as part of the participant's regimen.

Total RNA transcripts sequencing

CD4⁺ T cells were selected from cryopreserved PBMCs using EasySep Human CD4⁺ T Cell Enrichment Kit (STEMCELL Technologies). RNA was extracted from selected CD4⁺ T cells with the AllPrep DNA/RNA kit (Qiagen) with subsequent ribosomal RNA depletion RNA reverse transcribed to complementary DNA library and sequenced by NovaSeq (Illumina). Sequencing results were processed with the VIPER pipeline for alignment, counting and quality control⁹⁰. DEG analysis was performed with DESeq2 package⁸⁹ and GSEA with fgsea package using the adaptive multilevel splitting Monte Carlo approach ($n = 10,000$ for simple fgsea in preliminary estimation of P values)⁹¹.

Integration site identification and epigenetics

We characterized single proviral genomes along with their matched genomic integration sites by MIP-seq³⁹. Briefly, we initiated whole-genome amplification by performing multiple displacement amplification with phi29 polymerase using the QIAGEN REPLI-g Single Cell Kit, following the manufacturer's protocol. Afterward, we divided DNA from each sample and carried out proviral sequencing and integration site analysis. We utilized integration site loop amplification, which has been previously described, to obtain the integration sites associated with each viral sequence⁹². One modification that we made to this assay is targeting both the 5' and 3' ends of HIV to assess the integration site on both ends and eliminate any potential bias that may arise from analyzing only one end of HIV. To determine the exact location of HIV in the host gene, we used an online tool for trimming integration sites^{93,94}. We analyzed our integration sites for various histone marks by utilizing ChIP-seq datasets from primary CD4⁺ T cells that were publicly available on the ROADMAP website⁴⁰. The NIH Roadmap Epigenomics Mapping Consortium produces a public resource of human epigenomic

data to catalyze basic biology and disease-oriented research (<http://www.roadmapepigenomics.org/>). We calculated the total number of peaks of histone marks in a 10-kb window from the flanking sides of the integration site and regarded it as the total peak number. To determine the distance between the IS and the nearest TSS, we employed 'nearestTSS: Find Nearest Transcriptional Start Site', which is a tool developed and included in the edgeR package⁹⁵.

Inflammatory soluble marker levels

Cryopreserved plasma samples were thawed and analyzed in batch to assess inflammatory cytokines. Assays were run on 96-well plates. Duplicates were performed for 25% of the samples that were run on each plate. Mesoscale Discovery single and multiplex assays were performed according to instructions provided in kits for assessment of sCD14 (F21T1-2), sCD163 (F21J4-3), TNF-RI (R210V-3), TNF-RII (F21ZS-3), IFN- γ , IL-6, IL-10, IP-10, C-reactive protein (K151A9H-1) and TGF- β 1-3 (K15241K-1). D-dimer levels were measured with a standard enzyme-linked immunosorbent assay (Diagnostica Stago S.A.S.). The Mesoscale assays were analyzed with a MESO QuickPlex SQ 120MM Reader.

T cell activation phenotyping and assessment of surface CD4⁺ expression

PBMCs were thawed and stained with Live/Dead Violet (Thermo Fisher, 1:1,000), PE-Cy7-CD3 (clone SK7, BioLegend, 1:100), BV711-anti-CD4 (clone RPA-T4, BioLegend, 1:100), APC-anti-CD8 (clone SK1, BioLegend, 1:100), Alexa Fluor 700-anti-CD25 (clone M-A251, BioLegend, 1:50), BV650-anti-CD38 (clone HB-7, BioLegend, 1:50), FITC-anti-CD69 (FN50, BioLegend, 1:50), BV785-anti-HLA-DR (clone L243, BioLegend, 1:50) and PE/Dazzle 594-anti-PD-1 (clone EH12.2H7, BioLegend, 1:100). Cells were washed and fixed in 2% paraformaldehyde before flow cytometric analysis on a BD LSR Fortessa (BD Biosciences). CD4 surface expression was determined by assessment of CD4 mean fluorescence intensity.

Assessment of HIV-specific CD8⁺ T cell reactivity

PBMCs were resuspended at 1×10^6 ml⁻¹ in RPMI supplemented with 10% fetal bovine serum (R10) and plated 200 μ l per well in Immobilon-P 96-well microtiter plates (Millipore) precoated with 2 μ g ml⁻¹ anti-IFN- γ (clone DK1, Mabtech). Individual HLA-restricted HIV peptides from the optimal A-list⁹⁶ matched to each subject's HLA genotype were added at 1 μ g ml⁻¹ and incubated at 37 °C overnight. Negative control wells did not receive peptide and positive control wells were treated with 1 μ g ml⁻¹ anti-CD3 (clone OKT3, BioLegend) and 1 μ g ml⁻¹ anti-CD28 (clone CD28.8, BioLegend) antibodies. ELISPOT assay was performed using manufacturer's protocol with anti-IFN- γ (clone 1-DK1, Mabtech) capture, biotinylated anti-IFN- γ (clone B6-1, Mabtech) detection, Streptavidin-ALP (Mabtech) and AP Conjugated Substrate (Bio-Rad) followed by disinfection with 0.05% Tween-20 (Thermo Fisher) and analysis using S6 Macro Analyzer (CTL Analyzers). Responses greater than ten spots per well and 3-fold above negative controls were scored as positive^{97,96}.

Assessment of HIV-specific CD8⁺ T cell proliferation

PBMCs were stained at 37 °C for 20 min with 0.5 μ M CellTrace carboxyfluorescein succinimidyl ester (CFSE) (Thermo Fisher) as per manufacturer's protocol at 1×10^6 cells ml⁻¹. Staining was quenched with fetal bovine serum (Sigma), and cells were washed twice with R10, resuspended at 1×10^6 ml⁻¹ and plated 200 μ l per well in 96-well round-bottom polystyrene plates (Corning). Individual HIV peptides corresponding to IFN- γ ELISPOT responses for each participant were added at 1 μ g ml⁻¹ and incubated at 37 °C for 6 days before flow cytometric assessment. Negative control wells received dimethyl sulfoxide (in amounts equivalent to peptide containing wells), but no peptide. Positive control wells received 1 μ g ml⁻¹ anti-CD3 (clone OKT3, BioLegend) and anti-CD28 (clone CD28.8, BioLegend)

antibodies. On day 6, cells were stained with Live/Dead Violet (Thermo Fisher), PE/Cy7-anti-human CD3 (clone SK7, BioLegend) and APC-anti-human CD8 (clone SK1, BioLegend) and then analyzed by flow cytometry (Supplementary Fig. 4). The frequency of proliferating CD8⁺ T cells was determined by subtracting the percentage of CD8⁺ T cells in the CFSE low gate following HIV peptide stimulation by the highest percentage of CFSE low cells among the dimethyl sulfoxide negative controls.

HLA typing and HIV escape mutation data analysis

HLA-A/B/C typing was performed using sequence-specific oligonucleotide probing and sequence-based typing as previously described⁹⁸. We excised individual HIV genes from proviral sequences using Gene Cutter¹⁰⁶. We then identified polymorphisms within these genes that are known to be associated with one or more host HLA alleles expressed, as defined using a published list of HLA-associated polymorphisms across the HIV subtype B proteome⁹⁹. For the escape mutation analysis, each HLA-associated viral site was categorized into one of three groups: (1) 'non-adapted' viral sites showed the specific HIV-1 residue predicted to be susceptible to the restricting HLA, (2) 'adapted' sites showed the specific HIV-1 residue predicted to confer escape from the restricting HLA, and (3) 'possibly adapted' sites showed any residue other than the 'non-adapted' form, supporting it as a possible escape variant¹⁰⁰.

Limiting dilution VOA

PBMCs from participants and donors without HIV were stimulated with IL-2 (100 U ml⁻¹) and PHA (1 μ g ml⁻¹) for 72 h in R20 culture media. Then, we continued the stimulation with only with IL-2 in R20 culture media. VOAs were performed by using CD4⁺ T cells isolated from cryopreserved PBMCs using EasySep Human CD4⁺ T Cell Enrichment Kit (STEMCELL Technologies) from participants and healthy donors. Then we used MOLT-4/CCR5 cell lines and co-cultured those for more than 30 days, as reported previously¹⁰¹. We started with 0.1×10^6 MOLT-4/CCR5 cells and 0.5×10^6 CD4⁺ T cells from our participants and healthy donor and cultured them in each well of a 24-Transwell plates (STEMCELL Technologies). We collected samples from supernatant and MOLT-4/CCR5 every 3 days and refreshed the media with IL-2 (100 U ml⁻¹) in R20^{102,103}.

Statistical analysis

We analyzed our results by using Mann–Whitney *U* tests (two-tailed), Fisher's exact tests and Wilcoxon's tests as appropriate, unless otherwise specified. Correlations were tested by the Spearman's rank test. Adjustment for multiple comparisons was made in the analysis of ChIP-seq histone marks and host gene transcription, RNA-seq and numbers of HLA escape mutations per HIV-1 gene. A *P* value of less than 0.05 was deemed significant. We adjusted for multiple comparisons in the analysis of ChIP-seq histone marks and host gene transcription, RNA-seq and the number of HLA escape mutations per HIV-1 gene. However, we did not make any corrections for multiple comparisons in the other analyses, as it was an exploratory analysis. We performed the statistical analysis using Prism (GraphPad v.7) and the statistical packages in R (R Project for Statistical Computing, version 4.1.0).

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

All data and code are available by request to the authors and the AIDS Clinical Trials Group. Sequence data were submitted to Genbank (BioProject: [PRJNA973660](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA973660)). ROADMAP epigenomic data are available at <http://www.roadmapepigenomics.org>.

Code availability

There were no new pipelines or packages generated in this study. CHIP-seq and RNA-seq downstream data analyses code was deposited at <https://github.com/yijiali89/NSV>.

References

- Zheng, J. H. et al. Application of an intracellular assay for determination of tenofovir- diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. *J. Pharm. Biomed. Anal.* **122**, 16–20 (2016).
- Tosiano, M.A., Jacobs, J.L., Shutt, K.A., Cyktor, J.C. & Mellors, J.W. A Simpler and More Sensitive Single-Copy HIV-1 RNA Assay for Quantification of Persistent HIV-1 Viremia in Individuals on Suppressive Antiretroviral Therapy. *J Clin Microbiol* **57**(2019).
- Jiang, C. et al. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. *Nature* **585**, 261–267 (2020).
- Cornwell, M. et al. VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis. *BMC Bioinforma.* **19**, 135 (2018).
- Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
- Korotkevich, G., et al. Fast gene set enrichment analysis. *bioRxiv*, 060012 (2021).
- Wagner, T. A. et al. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. *Science* **345**, 570–573 (2014).
- Sibley, T. R., Silberman, E. J. & Mullins, J. I. ISDB: a database toolkit for storing and analyzing viral integration site data. *Bioinformatics* **35**, 1073–1075 (2019).
- Llano, A., Cedeño, S., Arrieta, S. & Brander, C. The 2019 Optimal HIV CTL epitopes update : Growing diversity in epitope length and HLA restriction. *Los Alamos National Laboratory* (2019).
- Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2009).
- Gaiha, G. D. et al. Structural topology defines protective CD8(+) T cell epitopes in the HIV proteome. *Science* **364**, 480–484 (2019).
- Garcia-Bates, T. M. et al. Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes. *EBioMedicine* **63**, 103175 (2021).
- Apps, R. et al. Influence of HLA-C expression level on HIV control. *Science* **340**, 87–91 (2013).
- Carlson, J. M. et al. Correlates of Protective Cellular Immunity Revealed by Analysis of Population-Level Immune Escape Pathways in HIV-1. *J. Virol.* **86**, 13202–13216 (2012).
- Warren, J.A., et al. The HIV-1 latent reservoir is largely sensitive to circulating T cells. *Elife* **9**(2020).
- Laird, G. M. et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. *PLoS Pathog.* **9**, e1003398 (2013).

Acknowledgements

We are grateful for the contributions of the participants who made this study possible. We thank the investigators and study staff of the AIDS Clinical Trials Group. We appreciate the support of the staff at the MGH sequencing core facility. We thank J. J. Szela for help with enrollment, T. J. Mitsutoshi Tamura for his valuable feedback. We thank Z. Herbert and his group from the Molecular Biology Core Facilities (MBCF) at the Dana-Farber Cancer Institute (DFCI) and the Advanced

Lab Technologies Core from the Harvard University Center for AIDS Research in Boston, MA for their assistance with the RNA-seq. This work was supported in part by the Harvard University Center for AIDS Research (AI060354), NIH grants AI169768 (J.Z.L.), UM1AI164560 (to S.G.D.), UM1 AI068634, UM1 AI068636, UM1 AI106701, R37AI039394 (A.N.E.), U54AI170791 (A.N.E.), DP2 AI154421 (G.D.G.) and a Burroughs Wellcome Career Award for Medical Scientists (G.D.G.). Y.L. was supported by Rustbelt CFAR (Case Western Reserve University/ University Hospitals Cleveland Medical Center and University of Pittsburgh, P30 AI036219). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. This research was supported in part by the Intramural Research Program of the NIH, Frederick National Lab, Center for Cancer Research. This project has been funded in part with federal funds from the Frederick National Laboratory for Cancer Research, under contract no. 75N91019D00024 (to M.C.). Z.L.B. is supported by a Scholar Award from Michael Smith Health Research BC.

Author contributions

A.M., B.E., X.Z., Y.L., R.S., D.R.K. and J.Z.L. conceived, designed and supervised the project; A.M., B.E., X.Z., Y.L., R.S., A.K., M.M., C.W., J.F., D.P.W., A.R., H.J., N.J., S.G.D., M.M.L., S.Y., D.R.K., A.T. and J.Z.L. participated in sample collection; A.M., B.E., F.G., E.G., R.C., S.A., T.A., A.S. and J.Z.L. performed sample processing; A.M., B.E., X.Z., Y.L., R.S., A.K., M.M., C.R.C., A.K.T., C.W., J.F., D.D., S.S. and J.Z.L. performed the experiments. A.M., Y.L., R.D. and Z.L.B. performed the statistical analysis; A.M., B.E., X.Z., Y.L., G.J.B., R.S., A.K., M.M., C.R.C., A.K.T., X.L., R.D., C.K., P.L.A., M.D.L., M.C., Z.L.B., J.R.C.M., A.N.E., G.D.G., D.D., S.S. and J.Z.L. participated in data collection and analysis; A.M., B.E., Y.L., R.S. and J.Z.L. wrote the original draft of the paper; all of the authors contributed to the final review of the paper and the editing.

Competing interests

J.R.C.M. has received funding from Gilead Sciences for investigator-initiated research paid to his institution. P.L.A. has received past consulting fees from Gilead, ViiV and Merck and research funding from Gilead paid to institution, unrelated to this work. G.D.G. has received grant funding from Merck. J.Z.L. has consulted for Abbvie and received grant funding from Merck. The other authors declare no competing interests.

Additional information


Extended data is available for this paper at <https://doi.org/10.1038/s41591-023-02611-1>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41591-023-02611-1>.


Correspondence and requests for materials should be addressed to Jonathan Z. Li.

Peer review information *Nature Medicine* thanks Jean-Pierre Routy and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor Alison Farrell, in collaboration with the *Nature Medicine* team.

Reprints and permissions information is available at www.nature.com/reprints.




Extended Data Fig. 1 | Viral load and CD4⁺ T cell count for seven NSV participants (Supplementary to Fig. 1). The table in each figure panel shows presence or absence of drug resistance mutations from both clinical testing and the largest plasma clone from single-genome sequencing. The “(C)” denotes a clinical resistance testing result.



Extended Data Fig. 2 | Reservoir size and composition for non-suppressible viremia participants (Supplementary to Fig. 2). (a) Comparison of proportion of the proviral and plasma HIV sequences comprised of each producer clone.

Red dotted lines represent higher plasma clone frequency and blue dotted lines present higher proviral clone frequency. (b) and (c) Percentage of intact and defective proviral species for each NSV participant.






Extended Data Fig. 3 | See next page for caption.

Extended Data Fig. 3 | Integration site features (Supplementary to Fig. 3).

(a) Correlation between enrichment of histone marks in producer integration sites and transcripts per million (TPM) from CD4⁺ T cell bulk RNA-seq results of each corresponding host gene harboring a provirus. On x-axis, total peak numbers in ± 10 kb flanking regions of $n = 11$ producer, $n = 21$ nonproducer and $n = 44$ defective integration sites from NSV samples were compared to each host gene TPM in their CD4⁺ T cells on y-axis. Two-sided Spearman correlation tests were used for the comparisons. (b) The distance of integration sites in each class of proviruses to the nearest transcriptional start sites (TSS). (c) The distance between the integration site to the TSS when HIV-1 or host genes are in the same orientation. (d) The distance between the integration site to the TSS when HIV-1 or host genes are in the opposite orientation. For figures b-d, $n = 11$ producer, $n = 21$ nonproducer and $n = 44$ defective integration sites from NSV samples were compared to each other. (e) The distance from the integration sites of different proviral classes to the centromere. Two-sided Kruskal-Wallis and Mann-Whitney U tests were used for comparisons. (f) Fraction of integration sites in speckle-associated domains (SPADs). Chi-squared test was used for comparisons. (g) Transcriptomic level of HIV host genes for producers, non-


producers and defectives. For (e)-(g), $n = 11$ producer, $n = 21$ nonproducer and $n = 44$ defective integration sites from NSV samples were compared to each other. (h) Transcriptomic level of host genes for producers, non-producers and defectives categorized by directionality to closest host genes. We compared the number of transcripts per million cells for the host gene of each integrated provirus, including categorizing by the relative direction of the provirus to the host gene. "+" represents human and HIV genome in the same and "-" represents human and HIV in the opposite orientation of their transcriptions. Total of $n = 11$ producer (5 integrations site in the same and 6 in the opposite orientation), $n = 21$ nonproducer (7 integrations site in the same and 14 in the opposite orientation) and $n = 44$ defective (20 integrations site in the same and 24 in the opposite orientation) integration sites from NSV samples were compared to each other. All the boxplots in this figure are in the format of the Tukey boxplot, with the center line indicating median, box limits indicating upper and lower quartiles and the whiskers indicating 1.5x interquartile range. Two-sided Kruskal-Wallis or Mann-Whitney U tests was used for comparisons, if not otherwise specified. For P values, ns, not significant.



Extended Data Fig. 4 | See next page for caption.


Extended Data Fig. 4 | Transcriptomic analysis of CD4 + T cells from NSV and ART-suppressed participants (Supplementary to Fig. 4). (a) Gene Set Enrichment Analysis (GSEA) plots show selected pathways that were up- or down-regulated in NSV vs. ART-suppressed (control) groups. Adjustments were made for multiple comparisons using the Benjamini-Hochberg method. (b)

Two-sided Wilcoxon rank sum test was used to evaluate interferon (IFN)-related gene expression levels between NSV and control groups. Bars represent median values. (c) Gene network related to IFN signaling enriched in the control group generated by STRING analysis.




Extended Data Fig. 5 | Soluble inflammatory markers in NSV versus ART-suppressed participants. (a) IL-10. (b) IL-6. (c) IFN- γ . (d) TGF- β 1, (e) TGF- β 2, (f) TGF- β 3, (g) TNF-RI, (h) TNF-RII, (i) CD-163, (j) D-Dimer, (k) CRP and (l) soluble

CD14 in NSV and ART-suppressed cohorts. Center lines indicated median levels and dotted lines indicated the first and third quartiles. The two-sided Mann-Whitney U test was used for comparisons.




Extended Data Fig. 6 | Viral load and CD4 + T cell features among NSV, ART-suppressed, and viremic controller cohorts. (a) Viral load of participants in NSV, ART-suppressed and viremic controller (VC) cohorts. (b) Mean fluorescence

intensity (MFI) values of CD4 in NSV, ART-suppressed, and VC cohorts. (c) Frequency of CD4 + T cells. Center lines indicated median levels and dotted lines indicated the first and third quartiles. Two-sided Mann-Whitney U test was used.



Extended Data Fig. 7 | HIV-specific CD8⁺ T cell response among NSV, ART-suppressed, and viremic controller cohorts. For Gag-specific CD8⁺ T cell response, we had n = 4, n = 6 and n = 8 responses for NSV, ART-suppressed and VC samples, respectively. For Pol-specific response, we had n = 1, n = 2 and n = 7 responses from NSV, ART-suppressed and VC samples, respectively. For Env-specific response, we had n = 2, n = 3 and n = 6 responses from NSV,

ART-suppressed and VC samples, respectively. For Nef-specific response, we had n = 3, n = 5 and n = 6 responses from NSV, ART-suppressed and VC samples, respectively. Bars represented median values and error bars indicated 95% confidence interval. Two-sided Kruskal-Wallis test was used to detect differences among three different cohorts. SFU, spot forming unit.




Extended Data Fig. 8 | HLA class I escape mutations by different HIV-1 genes. Average number of adapted and possible adapted HLA escape mutations in producer, non-producer, and defective proviral sequences across the HIV-1 genome (normalized for gene size) among eight participants with NSV. Center

lines in boxplots indicated median, box limits indicated upper and lower quartiles and the whiskers indicated minimal and maximal values. Friedman test was conducted within each gene area and Nemenyi post-hoc pair-wise tests were performed to evaluate the difference between two different proviral groups.



Extended Data Fig. 9 | Location of deletions in the 5' leader sequence in three NSV participants. Deletions are shown in the black regions at the bottom. Ψ , PSI element; SL1, stem loop; SL2, stem loop; DIS, dimerization initiation site; MSD, major splicing donor.



Extended Data Fig. 10 | Neighbor joining trees of LV9 trimmed either to the *pol-env* or *pol* regions. (a) Proviral and plasma sequences trimmed to the *pol-env* region. This panel is reproduced from Fig. 2a. (b) Proviral and plasma sequences trimmed on the *pol* region alone showing an inability to discriminate between two clonal populations seen with *pol-env* sequencing.

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection ROADMAP epigenomic data (available at <http://www.roadmapepigenomics.org>)

Data analysis Prism (GraphPad version 8.2.1) (<https://www.graphpad.com/scientific-software/prism/>, version 8.2.1)
 R (version 4.1.0) (<https://www.r-project.org>, version 4.1)
 Tidyverse (<https://tidyverse.tidyverse.org>, version 2.0.0)
 ggpubr (<https://rpkgs.datanovia.com/ggpubr/>, version 0.6.0)
 ggsci (<https://github.com/nanxstats/ggsci>, version 3.0.0)
 dunn.test (<https://CRAN.R-project.org/package=dunn.test>, version 1.3.5)
 Gene cutter: https://www.hiv.lanl.gov/content/sequence/GENE_CUTTER/cutter.html (no version available, last modified: Thu Sep 26 13:20 2019)
 MAFFT v7.2.0 (<https://mafft.cbrc.jp/alignment/server/>)
 MEGA 6 (<https://www.megasoftware.net/>)
 Proviral intactness pipeline (no version number available, <https://github.com/BWH-Lichterfeld-Lab/Intactness-Pipeline>)
 The Stanford HIV database (Version 9.4)
 VIPER pipeline (no version number, <https://bitbucket.org/cfce/viper/src/master/>)
 DESeq2 package (version 1.40.2)
 Integration site analysis (no version number): <https://indra.mullins.microbiol.washington.edu/integrationsites/>
 nearestTSS (from edgeR v3.42): Find Nearest Transcriptional Start Site
 S6 Macro Analyzer (Immunospot 7.0.38.3 Professional DC, Cellular Technology Ltd.)
 Adobe Illustrator (<https://www.adobe.com/products/illustrator.html>, version 2022 (26.1))
 Biorender (<https://biorender.com>)

PMCMRplus (version 1.9.7)
 Cytoscape version 3.10.1
 FlowJo Version 9.0.1 (<http://flowjo.com>)
 fgsea (version 1.26.0)
 BD FACSDiva (version 8.0.2)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

All data are available by request. Correspondence and requests for materials should be addressed to Dr. Jonathan Li (jlili@bwh.harvard.edu).

Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	We have reported the sex and race in Table 1 of the manuscript
Population characteristics	Population characteristics are reported in Table 1 of the manuscript.
Recruitment	We enrolled 8 ART-treated participants with ≥ 3 HIV-1 RNA levels between 40-1000 copies/mL over 24 months and compared them to a group of ART-suppressed participants and viremic controllers with similar demographic and HIV characteristics. The ART-suppressed and viremic controller comparators included participants from the AIDS Clinical Trials Group (ACTG) and the Ragon Institute of Mass General, MIT and Harvard. Sex and/or gender of participants was determined based on self-report.
Ethics oversight	All study participants provided written informed consent. The study was approved by the Mass General Brigham Institutional Review Board.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	A total of n=8 ART-treated participants with ≥ 3 HIV-1 RNA levels between 40-1000 copies/mL over 24 months called non-suppressible HIV-1 viremia (NSV), n=11 ART-suppressed participants from the AIDS Clinical Trials Group (ACTG), n=7 ART-suppressed participants from the Ragon Institute of MGH, MIT and Harvard and n=7 viremic controllers from the Ragon Institute of Mass General, MIT and Harvard. Written informed consent was obtained from all participants. Participants were analyzed in data described in Figure 1-5. Sample size was not calculated and was determined based on sample availability, as NSV is not an extremely common event and there is certain difficulty to recruit and collect sample from PWH with NSV. Previous studies on this topic usually included less than 5 sample and we included 8 here. We are not aware of significant self-selection bias.
Data exclusions	No data were excluded
Replication	Large clonal clusters were confirmed with multiple identical proviral and plasma RNA sequences. Positive and negative controls were included in the experiments.
Randomization	No randomization was performed as participants were already assigned as NSV or virally suppressed based on their clinical viral load data.

Blinding

No blinding was performed and sample names were labeled based on their de-identified ID, sample collection date and time points. No blinding was done to avoid sample cross-contamination.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

- | | |
|-------------------------------------|---|
| n/a | Involved in the study |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Antibodies |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Eukaryotic cell lines |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology and archaeology |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Animals and other organisms |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Clinical data |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Dual use research of concern |

Methods

- | | |
|-------------------------------------|--|
| n/a | Involved in the study |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq |
| <input type="checkbox"/> | <input checked="" type="checkbox"/> Flow cytometry |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> MRI-based neuroimaging |

Antibodies

Antibodies used

Live/Dead Violet (Thermo Fisher Cat# L34954, Lot# 2615872, 1:1000)
 PE-Cy7-CD3 (clone SK7, Biolegend Cat# 344816, Lot# B385424, 1:100),
 BV711-anti-CD4 (clone RPA-T4, Biolegend Cat# 300558, Lot# B354515, 1:100)
 APC-anti-CD8 (clone SK1, Biolegend Cat# 344722, Lot# B340556, 1:100)
 Alexa Fluor 700-anti-CD25 (clone M-A251, Biolegend Cat# 356118, Lot# B302029, 1:50)
 BV650-anti-CD38 (clone HB-7, Biolegend Cat# 356619, Lot# B370845, 1:50)
 FITC-anti-CD69 (FN50, Biolegend Cat# 310904, Lot# B290844, 1:50)
 BV785-anti-HLA-DR (clone L243, Biolegend Cat# 307641, Lot# B367913, 1:50)
 PE/Dazzle 594-anti-PD-1 (clone EH12.2H7, Biolegend Cat# 329940, Lot# B367981, 1:100)
 Carboxyfluorescein succinimidyl ester (CFSE; Life Technologies Cat# C34554, Lot# 2633292, 0.5 µM)

Validation

Antibodies are routinely used for highly expressed cell surface markers

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

MOLT-4/CCR5 cell line were used for viral outgrowth. Cell lines were obtained directly from the NIH AIDS Reagent Program (<https://www.niaid.nih.gov/research/nih-aids-reagent-program> and <https://www.hivreagentprogram.org/Catalog/HRPCellLines/ARP-4984.aspx>)

Authentication

Cell lines were obtained directly from the NIH AIDS Reagent Program, which authenticates and distributes HIV reagents (<https://www.niaid.nih.gov/research/nih-aids-reagent-program>). We further authenticate the cell line based on morphology.

Mycoplasma contamination

No contamination by mycoplasma was observed

Commonly misidentified lines (See [ICLAC](#) register)

No commonly misidentified cell lines were used

Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration

Study protocol

Data collection

Outcomes

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

PBMCs were stained at 37°C for 20 minutes with 0.5 μM CellTrace CFSE (Thermo Fisher) as per manufacturer's protocol at 1x10⁶ cells/mL. Staining was quenched with FBS (Sigma), cells were washed twice with R10, resuspended at 1x10⁶/mL and plated 200 μL per well in 96-well round-bottom polystyrene plates (Corning). Individual HIV peptides corresponding to IFN-γ ELISPOT responses for each patient were added at 1 μM and incubated at 37°C for 6 days before flow cytometric assessment. Negative control wells did not receive peptide and positive control wells received 1 μg/mL anti-CD3 (clone OKT3, Biolegend) and anti-CD28 (clone CD28.8, Biolegend) antibodies. On day 6, cells were stained for viability using Live/Dead Violet (Thermo Fisher), AlexaFluor700-anti-CD3 (clone SK7, Biolegend), BUV395-anti-CD8 (clone RPA-T8, BD Biosciences), and APC-pHLA tetramer matching the peptide used for stimulation, then analyzed by flow cytometry.

For activation marker staining, peripheral blood mononuclear cells (PBMC) were thawed and stained for 20 min at room temperature with Live/Dead Violet (Thermo Fisher), PE-Cy7-CD3 (clone SK7, Biolegend), BV711-anti-CD4 (clone RPA-T4, Biolegend), APC-anti-CD8 (clone SK1, Biolegend), Alexa Fluor 700-anti-CD25 (clone M-A251, Biolegend), BV650-anti-CD38 (clone HB-7, Biolegend), FITC-anti-CD69 (FN50, Biolegend), BV785-anti-HLA-DR (clone L243, Biolegend), PE/Dazzle 594-anti-PD-1 (clone EH12.2H7, Biolegend). Cells were washed and fixed in 2% paraformaldehyde prior to flow cytometric analysis on a BD LSR Fortessa (BD Biosciences). CD4 surface expression was determined by assessment of CD4 mean fluorescence intensity (MFI).

Instrument

BD Biosciences LSR II

Software

BD FACS Diva was used for data acquisition. FlowJo Version 9.0.1 was used to analyze the data.

Cell population abundance

The relevant CD3+CD8+CFSElow T cells ranged from 0.1-7% of CD3+CD8+ T cells

Gating strategy

For CFSE-based proliferation assays, we used the following gating strategy: FSC-A/SSC-A (lymphocytes), FSC-A/FSC-H (single cells), Viability Dye/SSC-A (live cells), CD3/SSC-A (CD3+ T cells), CD8/SSC-A (CD3+ CD8+ T cells), CD8/CFSE (CD3+CD8+CFSElow T cells).

For activation marker staining, FSC-A/SSC-A (lymphocytes), FSC-A/FSC-H (single cells), Viability Dye/SSC-A (live cells), CD3/SSC-A (CD3+ T cells), CD4/CD8 (CD3+CD4+ or CD3+CD8+ T cells), CD38/HLA-DR (CD3+CD4+CD38+HLA-DR+ or CD3+CD8+CD38+HLA-DR+ T cells, activated T cells)

- Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.